Genomic Testing and Data Updates for High Risk Early-Stage Breast Cancer Patients

2024 ASCO® Annual Meeting Insights Hub
E

ASCO® 2024 Insights: "Elucidating the Immune Active State of HR+/HER2- MammaPrint High 2 Early BC"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Erin Cobain
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Erin Cobain
316 views
June 18, 2024
0 Comments
Login to view comments. Click here to Login
09:10
Adam Brufsky

Brief Update on Genomic Assays for Early Stage Breast Cancer

12:57
Tiffany Onger

Unequal Outcomes: Disparities in Breast Cancer for Black Women

12:08
UChicago Medicine

Racial Disparities in Breast Cancer Screening and Diagnosis

Feat. N. Chen
27:15
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Management of Higher Risk eBC Including BR…

Feat. M. Dolezal
25:45
Han-Byoel Lee

Identifying Breast Cancer Subtypes and Recurrence Risk: Multigene As…

10:10
Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Summary: "Breaking New Ground With CDK 4/6i - …

Feat. W. Janni
12:14
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

Feat. P. Tarantino
04:04
Laurence Buisseret

Clinical Overview of IO Development in ER+/HER2- BC

14:40
Erin Cobain

Neoadjuvant Chemo-IO for HR+/HER2- BC

12:37
University of Colorado Cancer Center

Young Women With HR+/HER2- Breast Cancer: Options for Risk Assessment

Feat. V. Borges